Correspondence 0001193125-23-199179 from Dianthus Therapeutics, Inc. /DE/ (DNTH) (CIK 0001690585) (DNTH)
Dianthus Therapeutics, Inc. /DE/ (DNTH) (CIK 0001690585)
Date: July 31, 2023 · CIK: 0001690585 · Accession: 0001193125-23-199179
AI Filing Summary & Sentiment
File numbers found in text: 333-271917
Letter
Magenta Therapeutics, Inc.
300 Technology Square, 8th Floor
Cambridge, MA 02139
July 31, 2023
VIA EDGAR
Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street NE
Washington, DC 20549
Attention: Ms. Doris Stacey Gama
Mr. Jason Drory
Ms. Jenn Do
Mr. Kevin Vaughn
Re: Magenta Therapeutics, Inc.
Acceleration Request for Registration Statement on Form S-4
File No. 333-271917
Requested Date:
August 1, 2023
Requested Time:
4:15 p.m. Eastern Time
Dear. Ms. Gama, Mr. Drory, Ms. Do and Mr. Vaughn:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Magenta Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to August 1, 2023, at 4:15 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Marianne Sarrazin at (415) 733-6134. We also respectfully request that a copy of the written order from the Securities and Exchange Commission verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Marianne Sarrazin, by email to msarrazin@goodwinlaw.com or by facsimile to (415) 651-9491.
If you have any questions regarding this request, please contact Marianne Sarrazin of Goodwin Procter LLP at (415) 733-6134.
Sincerely,
Magenta Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Magenta Therapeutics, Inc. 300 Technology Square, 8th Floor Cambridge, MA 02139 July 31, 2023 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street NE Washington, DC 20549 Attention: Ms. Doris Stacey Gama Mr. Jason Drory Ms. Jenn Do Mr. Kevin Vaughn Re: Magenta Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-4 File No. 333-271917 Requested Date: August 1, 2023 Requested Time: 4:15 p.m. Eastern Time Dear. Ms. Gama, Mr. Drory, Ms. Do and Mr. Vaughn: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Magenta Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to August 1, 2023, at 4:15 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Marianne Sarrazin at (415) 733-6134. We also respectfully request that a copy of the written order from the Securities and Exchange Commission verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Marianne Sarrazin, by email to msarrazin@goodwinlaw.com or by facsimile to (415) 651-9491. If you have any questions regarding this request, please contact Marianne Sarrazin of Goodwin Procter LLP at (415) 733-6134. Sincerely, Magenta Therapeutics, Inc. /s/ Stephen Mahoney Stephen Mahoney President, Chief Financial and Operating Officer cc: Marianne Sarrazin, Goodwin Procter LLP William D. Collins, Goodwin Procter LLP Michael Patrone, Goodwin Procter LLP